Answers are grounded in this paper and cite their sources.
On December 10, 2021, the FDA published a Determination Letter, along with a Statistical Review and Evaluation Report, and concluded that under the non-informative prior, the local Bayesian optimal interval design (BOIN) design, in its revised form, can be designated fit-for-purpose for identifying the maximum tolerated dose (MTD) of a new drug, assuming that dose-toxicity relationship is monotonically increasing. Although setting the BOIN design parameter
No takes yet. Share an insight, caveat, or question.
Rong Lü (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: